Back
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Journal article

PD-L1 receptor expression in vulvar carcinomas is HPV-independent.

  • Choschzick M Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstr. 12, 8091, Zurich, Switzerland. Matthias.Choschzick@usz.ch.
  • Gut A Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstr. 12, 8091, Zurich, Switzerland.
  • Fink D Department of Gynecology, University Hospital Zurich, Frauenklinikstr. 10, 8091, Zurich, Switzerland.
  • 2018-05-09
Published in:
  • Virchows Archiv : an international journal of pathology. - 2018
HPV
PD-L1
Prognosis
Vulvar cancer
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
Biomarkers, Tumor
Carcinoma, Squamous Cell
Female
Humans
Immunohistochemistry
Middle Aged
Neoplasm Grading
Neoplasm Staging
Papillomaviridae
Vulvar Neoplasms
English PD-L1 (programmed cell death 1 ligand) is expressed on many cancer cells and prevents tumor cell death by blocking T cell activity. PD-L1 overexpression has been reported in squamous cell carcinomas of head and neck and lung cancer. To better understand the role of PD-L1 expression in vulvar cancer, we analyzed PD-L1 expression by immunohistochemistry in 55 well-characterized squamous cell carcinomas of vulva. PD-L1 was found in 72.7% of tumors. 27.3% of vulvar carcinomas showed moderate or strong PD-L1 expression. PD-L1 expression was correlated with low tumor stage (p < 0.05). There was no association to other clinicopathological parameters, HPV status, and overall survival of vulvar carcinoma patients. In conclusion, PD-L1 overexpression is detectable in a substantial proportion of vulvar carcinomas in all stages independent of HPV and may be a suitable therapeutic target in these cancers.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/47535
Statistics
Document views: 16 File downloads: